current results, one year, per today's news release, they blow every other approved alzheimer's drug out of the water, it is not remotely close. And it cannot be close, as all the other drugs do not work.
Biib's fraud drug accounts for 35 billion in market cap, and has no other applications whatsoever (it does not work in the first place!)....SAVA's drug will without a doubt, be applied to another dozen major CNS applications, and possibly double or triple it's Alzheimers market, which is by far the biggest mmarket in pharma world history.
One DRUG TO RULE THEM ALL... TO $3,000. S/P
Even the FDA says that this year, alzheimer's will be the most costly disease in america (and the world).
What FDA does not say is the estimated market size of the other Central Nervous Systemr drugs, another near unimaginable market.
I expect SAVA to be bought out by year end. 3 months. 7 billion a steal. SAVA should do some stuff to make sure they are not bought for that price. An offer of 190 bucks is a no brainer.
In this way big pharma offers 4% of value at 7 bil.
a platform drug. One year of astounding efficiacy is automatic approval as every other drug cannot offer 30 days of effectiveness; they offer zero.
AI
Market Data 
Markets 
